Skip to main content
LIFECORE BIOMEDICAL, INC. \DE\ logo

LIFECORE BIOMEDICAL, INC. \DE\ — Investor Relations & Filings

Ticker · LFCR ISIN · US5147661046 LEI · 549300EHBZ5OM9ND9O43 US Manufacturing
Open in API
Filings indexed 1,096 across all filing types
Latest filing 2012-06-29 Director's Dealing
Country US United States of America
Listing US LFCR

About LIFECORE BIOMEDICAL, INC. \DE\

https://www.lifecore.com/

Lifecore Biomedical is an integrated contract development and manufacturing organization (CDMO) that specializes in sterile injectable pharmaceutical drug products and medical devices. The company provides a full range of services, including specialty formulation, process development, aseptic filling, and final packaging, supporting products from clinical phases through to commercial supply. A key area of expertise is the handling of complex and highly viscous formulations. In addition to its CDMO capabilities, Lifecore is a primary producer of non-animal-sourced sodium hyaluronate (hyaluronic acid), offering it in various molecular weights and formats, including bulk material, hydrogels, and filled syringes and vials for diverse applications.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2012-06-29 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K, which is a current report filed with the SEC to announce unscheduled material events or corporate changes. The text indicates that the company issued a press release about entering into agreements with another company, and the press release is attached as an exhibit. There are no financial statements or detailed financial data included in this document. The length is 2499 characters, which is relatively short and consistent with an announcement rather than a full report. The document does not contain quarterly or annual financial results, audit information, or management discussion. It is primarily an announcement of a corporate event via a press release. Therefore, this filing fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2012-06-27 English
OWNERSHIP DOCUMENT
Director's Dealing
2012-06-14 English
SCHEDULE 13D
Major Shareholding Notification
2012-06-14 English
FORM 8K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into material definitive agreements related to financing, including a credit agreement and a reimbursement agreement with a bank. It details the terms of the financing, covenants, and events of default. There are no financial statements or comprehensive financial performance data typical of annual or quarterly reports. The document is focused on financing activities and capital structure changes. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is over 6000 characters, so it is not a mere announcement of a report but the actual filing of the event.
2012-05-29 English
FORM 4
Director's Dealing
2012-05-23 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.